These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23529732)

  • 1. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
    Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
    Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
    Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
    Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
    PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.
    Dudley DM; Wentzel JL; Lalonde MS; Veazey RS; Arts EJ
    J Virol; 2009 May; 83(10):5067-76. PubMed ID: 19279098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
    Latinovic O; Reitz M; Le NM; Foulke JS; Fätkenheuer G; Lehmann C; Redfield RR; Heredia A
    Virology; 2011 Mar; 411(1):32-40. PubMed ID: 21232779
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Gracias S; El Yaalaoui I; Visseaux B; Charpentier C; Descamps D; Martin C; Lermechain F; Plantier J-C; Alessandri-Gradt E
    Microbiol Spectr; 2024 Jul; 12(7):e0389523. PubMed ID: 38809042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
    Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
    J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
    Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
    Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.